Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The primary purpose of this study is to test the efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT). This is a placebo controlled, cross-over clinical trial of oral Lisdexamfetamine Dimesylate 30-70mg/day in adults with attention-deficit hyper-activity disorder and Sluggish Cognitive Tempo (ACT). Patients will be assigned either LDX/Placebo for 10 weeks with a two week placebo washout period.
Epistemonikos ID: 8bcc312784c16c3d30b51f9f009ed4de913a0db6
First added on: May 12, 2024